4,920 Amgen Inc. $AMGN Shares Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 6.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 85,905 shares of the medical research company's stock after acquiring an additional 4,920 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al's holdings in Amgen were worth $36,210,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. raised its stake in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company's stock worth $17,874,974,000 after acquiring an additional 2,261,544 shares in the last quarter. State Street Corp boosted its stake in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company's stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Amgen by 12.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,390,910 shares of the medical research company's stock valued at $1,952,156,000 after purchasing an additional 605,928 shares in the last quarter. Bank of America Corp DE bought a new stake in shares of Amgen in the 2nd quarter worth about $1,831,903,000. Finally, Amundi grew its holdings in shares of Amgen by 15.2% in the 2nd quarter. Amundi now owns 3,890,189 shares of the medical research company's stock worth $1,408,715,000 after purchasing an additional 512,883 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock.

Amgen Stock Performance

Shares of Amgen stock opened at $466.01 on Friday. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. The firm has a market cap of $251.94 billion, a P/E ratio of 20.60, a P/E/G ratio of 3.37 and a beta of 0.41. The firm has a 50 day simple moving average of $419.96 and a 200 day simple moving average of $374.79. Amgen Inc. has a fifty-two week low of $288.00 and a fifty-two week high of $475.65.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Sell-side analysts predict that Amgen Inc. will post 22.96 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be paid a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen's dividend payout ratio is 62.65%.

Analyst Ratings Changes

A number of brokerages recently issued reports on AMGN. Piper Sandler increased their target price on shares of Amgen from $427.00 to $457.00 and gave the stock an "overweight" rating in a research report on Thursday, August 20th. Weiss Ratings raised shares of Amgen from a "buy (b)" rating to a "buy (b+)" rating in a research note on Thursday, October 8th. Oppenheimer reaffirmed an "outperform" rating on shares of Amgen in a report on Friday, October 23rd. Sanford C. Bernstein raised their price objective on shares of Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a report on Thursday, August 6th. Finally, HSBC cut shares of Amgen from a "buy" rating to a "hold" rating and cut their target price for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and a consensus target price of $389.71.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Dividend support: Amgen’s dividend announcement helped reinforce the stock’s income appeal and contributed to its move to a new 1-year high. Amgen Sets New 1-Year High Following Dividend Announcement
• Positive Sentiment: Analyst endorsement: RBC Capital reaffirmed its Buy rating, providing continued Wall Street support ahead of the earnings release. RBC Capital Reaffirms Buy Rating
• Positive Sentiment: Pipeline and rare-disease progress: New Phase 3 dazodalibep data in Sjögren’s disease, UPLIZNA updates and a rare-disease diagnostic collaboration support Amgen’s longer-term growth narrative beyond its established products. Rare Disease Updates
• Neutral Sentiment: Key near-term catalyst: Amgen will report third-quarter 2026 results after the market close on November 3. The current consensus EPS estimate cited in previews is $5.79, making earnings, guidance and management commentary important tests for the recent rally. Amgen Q3 2026 Preview
• Negative Sentiment: Profitability concerns: Management has warned of rising expenses, while MariTide development is consuming substantial cash. Investors are watching whether growth from Repatha and TEZSPIRE can offset higher costs and protect margins. Amgen Faces Rising Expenses Ahead of Q3 Results
• Negative Sentiment: Valuation and execution risk: A skeptical earnings preview highlights concerns about the CFO transition, spending growth and whether Amgen can meet expectations after a substantial year-to-date advance. Amgen Earnings Preview

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 2,970 shares of Amgen stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares of the company's stock, valued at $2,642,098.28. This represents a 23.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 6,222 shares of company stock worth $2,540,926 in the last ninety days. 0.85% of the stock is currently owned by insiders.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company's products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.